By D. Sanford. Lincoln University, San Francisco California.

Of these buy voveran 50 mg on line, 68 were trials (23 for Update 4) 50mg voveran otc, 47 were observational studies (4 for Update 4) order voveran 50 mg amex, 32 were systematic reviews (4 for Update 4) cheap voveran 50mg online, and 12 were pooled analyses and post-hoc analyses (2 for Update 4) discount 50 mg voveran visa. See Appendix E for a list of excluded studies and reasons for exclusion at full text. Figure 1 shows the flow of study selection for Update 4. Results of literature search b 1124 records identified from 15 additional records identified database searches after through other sources removal of duplicates 1139 records screened 990 records excluded at abstract level 149 full-text articles assessed 116 full-text articles for eligibility excluded • 6 non-English language • 5 ineligible outcome • 15 ineligible intervention • 14 ineligible population 31 studies (+2 companion • 15 ineligible publication type publications) included in qualitative synthesis • 45 ineligible study design • 21 trials (+2 companion • 16 outdated or ineligible publications) systematic reviews • 4 observational studies • 4 systematic reviews • 2 others (includes pooled analysis, post hoc analysis of trials, etc. Nonsteroidal antiinflammatory drugs (NSAIDs) 17 of 72 Final Report Update 4 Drug Effectiveness Review Project Key Question 1. Are there differences in effectiveness between NSAIDs, with or without antiulcer medication, when used in adults with chronic pain from osteoarthritis, rheumatoid arthritis, soft-tissue pain, back pain, or ankylosing spondylitis? Summary of Evidence Comparisons between oral drugs • Celecoxib 200 mg/day to 800 mg/day compared with nonselective NSAIDs o Associated with similar pain reduction effects in primarily short-term randomized controlled trials of patients with osteoarthritis, rheumatoid arthritis, soft tissue pain, and ankylosing spondylitis in 11 of 12 trials • Partially selective NSAIDs compared with nonselective NSAIDs o Partially selective NSAIDs (meloxicam, nabumetone, and etodolac) were associated with similar pain reduction effects relative to nonselective NSAIDs in short-term randomized controlled trials • Comparisons among nonselective NSAIDs o Good-quality Cochrane reviews and more recent trials found no clear differences among nonselective NSAIDs in efficacy for treating osteoarthritis of the knee or hip or for low-back pain o Evidence on the comparative efficacy of salsalate was limited to 2 randomized controlled trials that found no significant difference as compared with indomethacin. Comparisons between topical drugs • We found no trials that directly compared the effectiveness or efficacy between different topical drugs • Both diclofenac 1. Comparisons between oral and topical drugs • No significant differences were found between diclofenac 1. Nonsteroidal antiinflammatory drugs (NSAIDs) 18 of 72 Final Report Update 4 Drug Effectiveness Review Project Detailed Assessment Effectiveness Some trials evaluated longer-term (>6-12 months) and real-life (symptoms, clinical ulcers, functional status, myocardial infarctions, pain relief) outcomes, but none were conducted in primary care or office-based settings or used broad enrollment criteria. Efficacy: Comparisons between oral drugs Celecoxib compared with nonselective NSAIDs 22-30 Eleven of 12 randomized controlled trials of arthritis patients found no significant difference in efficacy between celecoxib and an NSAID. The single study finding a difference was a randomized controlled trial of 249 randomized patients with severe osteoarthritis of the hip requiring joint replacement surgery. A significantly greater reduction in pain on walking was found for diclofenac 50 mg 3 times daily compared with celecoxib 200 mg once daily, as measured using an 100 mm visual analog scale, both in the primary 6-week assessment (difference, 12. However, insufficient information was provided to determine if an adequate method was used to conceal the allocation sequence or whether the approach produced treatment groups that were comparable at baseline in terms of important prognostic factors. Baseline characteristics were only provided for the evaluable population (N=141), which only accounted for 60% of the modified intention-to-treat population (N=235). Consequently, this randomized controlled trial was rated poor quality and its results should be interpreted with caution. The Agency for Healthcare Research and Quality Effective Health Care Program 31 Comparative Effectiveness Review found no clear differences in efficacy between celecoxib 22, 24, 26, 29 32, 33 and nonselective NSAIDs based on results from published trials and meta-analyses of published and unpublished trials. Celecoxib and nonselective NSAIDs were associated with similar pain reduction effects (Western Ontario and McMaster Universities Osteoarthritis Index, visual analogue scale, Patient Global Assessment) in published trials of patients with 22, 24, 26, 29 34, 35 36-38 29, osteoarthritis, soft tissue pain, ankylosing spondylitis, or rheumatoid arthritis. Celecoxib 200-400 mg was associated with slightly higher rate of withdrawals than other NSAIDs due to lack of efficacy (relative risk, 1. This estimate of comparative efficacy may be the most precise available, but the validity of the findings cannot be verified as the data used in this analysis is not fully available to the 33 public. On the other hand, ibuprofen 2400 mg/day and diclofenac 150 mg/day were associated with higher rates of withdrawal due to lack of efficacy than celecoxib 800 mg/day after 52 weeks (14. Nonsteroidal antiinflammatory drugs (NSAIDs) 19 of 72 Final Report Update 4 Drug Effectiveness Review Project Partially selective NSAIDs compared with nonselective NSAIDs Partially selective NSAIDs (meloxicam, nabumetone, and etodolac) were associated with similar pain reduction effects relative to nonselective NSAIDs in short-term randomized controlled trials. In 2 of the trials, however, patients taking nonselective NSAIDs were significantly less likely to withdraw due to lack of efficacy 44, 49 than patients taking meloxicam. A systematic review of 3 short-term randomized controlled trials of nabumetone for soft tissue pain found no difference in efficacy when compared with 50 ibuprofen or naproxen. However, based on physician assessment, the same systematic review also found placebo to be as efficacious as nabumetone in reducing pain at 7 days. Etodolac and nonselective NSAIDs were generally associated with similar rates of withdrawals due to 51 52 efficacy or improvements in pain in short-term randomized controlled trials of patients with osteoarthritis of the knee and/or hip. A sustained-release form of etodolac was also associated with similar rates of pain reduction relative to diclofenac in a small trial (N=64) of patients with 53 osteoarthritis of the knee. Comparisons among nonselective NSAIDs Several recent good-quality systematic reviews by the Cochrane Collaboration found no clear 51 differences among nonselective NSAIDs in efficacy for treating osteoarthritis of the knee, 54 55 hip, or low-back pain. Results from 3 fair-quality randomized controlled trials published subsequent to the Cochrane reviews also consistently found no significant differences in efficacy 56-58 among nonselective NSAIDs when used in patients with osteoarthritis. Limited evidence from 2 trials found no difference in efficacy when salsalate 3 g daily 59 60 was compared with indomethacin 75 mg daily or diclofenac 75 mg daily. No studies comparing salsalate to other NSAIDs were identified, and salsalate was not included in any of the systematic reviews included in this report. Tenoxicam 20 mg and 40 mg, diclofenac, and indomethacin were associated with similar 61 effects on pain in a good-quality systematic review of 18 randomized controlled trials.

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain buy 50 mg voveran. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind purchase 50 mg voveran otc, placebo-controlled study trusted 50 mg voveran. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study generic 50mg voveran mastercard. Lacosamide in painful diabetic neuropathy: an 18- week double-blind placebo-controlled trial voveran 50mg otc. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Efficacy and safety of lacosamide in painful diabetic neuropathy. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Thienel U, Neto W, Schwabe SK, Vijapurkar U, Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double- blind placebo-controlled trials. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo- controlled study. Neuropathic pain 56 of 92 Final Update 1 Report Drug Effectiveness Review Project 99. Sindrup SH, Ejlertsen B, Froland A, Sindrup EH, Brosen K, Gram LF. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Sindrup SH, Gram LF, Skjold T, Grodum E, Brosen K, Beck-Nielsen H. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. Divalproex sodium in the management of post- herpetic neuralgia: a randomized double-blind placebo-controlled study. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Kochar DK, Jain N, Agarwal RP, Srivastava T, Agarwal P, Gupta S. Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM: monthly journal of the Association of Physicians.

discount voveran 50mg with amex

At the wrist both the ulnar artery and nerve lie lateral (radial) to • Other branchesainclude a nutrient artery to the humerus and flexor carpi ulnaris and pass over the flexor retinaculum giving carpal superior and inferior ulnar collateral branches which ultimately branches which contribute to the dorsal and palmar carpal arches cheap voveran 50mg visa. The reduced arterial flow results in ischaemic necro- is completed by the superficial palmar branch of the radial artery cheap 50 mg voveran with mastercard. In the classical deformity the forearm is wasted and the wrist joint flexed with the fingers extended discount 50mg voveran mastercard. When the wrist is The common interosseous artery extended the fingers flex buy voveran 50 mg with visa. The common interosseous artery is the first ulnar branch to arise and it subdivides into the: The radial artery • Anterior interosseous artery: descends with the interosseous branch • Course: the radial artery arises at the level of the neck of the radius of the median nerve on the anterior surface of the interosseous from the bifurcation of the brachial artery order voveran 50mg with visa. It predominantly supplies the flexor compartment of the don to lie firstly on supinator then descends on the radial side of the forearm. The radial artery passes sequentially runs with the deep branch of the radial nerve supplying the extensor over supinator, pronator teres, the radial head of flexor digitorum muscles of the forearm, eventually anastomosing with the anterior superficialis, flexor pollicis longus and pronator quadratus. They drain lymph from the ulnar side of the forearm As in the lower limb the venous drainage comprises interconnected and hand. Lymph from this group passes to the lateral group of axillary superficial and deep systems. This group is venous network overlying the anatomical snuffbox. It ascends the arranged around the cephalic vein in the deltopectoral groove. From lateral, then anterolateral, aspects of the forearm and arm and this point the efferent vessels pass through the clavipectoral fascia to finally courses in the deltopectoral groove to pierce the clavipec- drain into the apical group of axillary nodes and thence centrally. This information can be applied to the clinical scenario. If a patient • The basilic vein commences from the medial end of the dorsal presents with an infected insect bite of the thumb, the infraclavicular venous network. It ascends along the medial then anteromedial nodes would reactively enlarge. If, however, infection occurred on the aspects of the forearm and arm to pierce the deep fascia (in the patient’s little finger, lymphadenopathy of the supratrochlear nodes region of the mid-arm) to join with the venae comitantes of the would result. The two superficial veins are usually connected by a median cubital The breast (Fig. The breasts are present in both sexes and have similar characteristics • The deep veins: consist of venae comitantes (veins which accom- until puberty when, in the female, they enlarge and develop the capac- pany arteries). The breasts are essentially specialized skin The superficial veins of the upper limb are of extreme clinical import- glands comprising fat, glandular and connective tissue. The base of the ance for phlebotomy and peripheral venous access. The most com- breast lies in a constant position on the anterior chest wall. It extends monly used sites are the median cubital vein in the antecubital fossa and from the 2nd to 6th ribs anteriorly and from the lateral edge of the ster- the cephalic vein in the forearm. A part of the breast, the axillary tail, extends laterally through the deep fascia beneath pectoralis to enter Lymphatic drainage of the chest wall and the axilla. Each breast comprises 15–30 functional ducto-lobular units upper limb (Fig. The lobes are separated by fibrous Lymph from the chest wall and upper limb drains centrally via axillary, septa (suspensory ligaments) which pass from the deep fascia to the supratrochlear and infraclavicular lymph nodes. A lactiferous duct arises from each lobe and converges on the nipple. In its terminal por- Axillary lymph node groups tion the duct is dilated (lactiferous sinus) and thence continues to the There are approximately 30–50 lymph nodes in the axilla. The areola is the darkened arranged into five groups: skin that surrounds the nipple. Its surface is usually irregular due to • Anterior (pectoral) group: these lie along the anterior part of the multiple small tuberclesaMontgomery’s glands. They receive lymph from the upper anterior • Blood supply: is from the perforating branches of the internal part of the trunk wall and breast. The venous drainage corres- the medial wall of the axilla. They receive lymph from the upper pos- ponds to the arterial supply.

generic 50mg voveran with amex

Effective referral-based estimates of 1/100 000; the discrepancy implies that a methods to expand HSCs after gene correction would be useful 50 mg voveran free shipping. Another finding from the screening results to only are capable of integrating into the genome of dividing cells generic voveran 50 mg, but date is that the distribution of SCID genotypes is different from that most of the HSCs with long-term cell production activity are reported in some prior large buy voveran 50 mg online, single-center series buy cheap voveran 50mg line,16 with RAG1/2 quiescent 50 mg voveran with amex. Therefore, major efforts were made to identify hematopoi- defects much more common than previously detected ( 1/3 of etic growth factors that will stimulate HSCs to divide without identified genotypes), making XSCID and ADA-deficient SCID inducing terminal differentiation and loss of stem cell self-renewal responsible for a relatively smaller percentage of cases ( 35% and activity. A relatively standard mixture of cytokines has been used by 10%–15% respectively). The best approach to treating these infants remains to be dependent on stimulation of CD34 cell populations for effective determined. Because they are being diagnosed within the first few transduction than are -RVs, but the extent of gene transfer is weeks of life, earlier transplantation is possible; however, toxicities significantly increased when cells are prestimulated in the same from cytoreductive conditioning regimens may be heightened at this cytokine combinations before transduction. Therefore, the PIDTC is planning a vectors entail 1 day of prestimulation and 1 day of transduction, prospective clinical trial that will evaluate the role of low-dose compared with protocols for -RVs with 2 days of prestimulation busulfan cytoreductive conditioning in a gradual dose escalation and 2-3 days of transduction; the shorter culture for lentiviral Hematology 2014 477 transduction may better preserve stem cells and enhance engraft- -RV-modified CD34 BM transplantation did have some clustered ment polyclonality. ADA SCID was thereby the first UCL/GOSH is a self-inactivating (SIN) lentiviral vector carrying a disorder to be addressed with gene therapy, with trials in the 1990s codon-optimized human ADA cDNA under transcriptional control using -RVs carrying human ADA cDNA targeting either periph- of the human Elongation Factor 1-alpha gene “short” promoter. No significant clinical Preclinical studies performed jointly by the UK and US investiga- efficacy was seen, with relatively low levels of gene-modified cells tors showed that the EFS-ADA vector was produced at high titer, in the subjects. Most continued to receive PEG-ADA enzyme efficiently transferred the ADA cDNA to human BM CD34 cells replacement therapy that supported immune function but may have assayed in vitro and by NSG xenografts, expressed ADA enzyme obscured potential effects from the transplantation. The major advance in the pioneering studies at San Raffaele-Telethon Institute for Gene XSCID Therapy (TIGET) was the adoption of nonmyeloablative condition The results of the first clinical trials of gene therapy for XSCID with busulfan (4 mg/kg) before the transplantation of the ADA 20 using -RVs to carry a normal human IL2Rg ( c) cDNA in Paris, gene-modified CD34 cells. The initial report of immune reconsti- 28-30 France, and London are well known. Significant T-cell immune tution in 2 subjects was extended to at least 18 subjects treated, with reconstitution occurred in the majority of subjects, only limited in successful immune reconstitution in most, which has persisted with 21 those with severe preexisting infections at the time of transplanta- no late adverse events. B-cell functional recovery was less consistent, although half of (UCL)/Great Ormond Street Hospital (GOSH) and University of the subjects have sufficient B-lymphoid activity to be able to California, Los Angeles (UCLA)/National Institutes of Health discontinue gamma-globulin replacement. The earliest treated sub- (NIH) have confirmed similar responses using retroviral vectors and 22-24 ject is out 15 years with sustained normal T-cell counts, continued similar low-dose busulfan conditioning. The majority developed protective immunity and However, 5 of 20 subjects between the 2 trials developed T- remain well without other interventions, such as enzyme replace- lymphoid leukemia-like leukoproliferative complications 2-5 years ment or allogeneic HSCT. In our studies of 20 ADA-deficient SCID 31-33 after gene therapy. This proved fatal in 1 case, but was subjects, we have observed the most robust levels of immune reversible in 4 with ALL-type therapy; there have been no new reconstitution in infants treated at 1 year of age, and less cases occurring after 5 years. The cause is the process of insertional improvement of immune function in older subjects (eg, 4-15 years). Despite these subjects and, therefore, their grafts had larger cell doses than for the serious complications, 90% of the subjects are surviving, with 85% older subjects. Importantly, there have been no vector-related having sustained immune reconstitution, results at least equivalent complications in any of the ADA-SCID patients, in sharp contrast to to those using HLA-matched related donors. The basis for this difference is unknown; specula- cells across their different trials for ADA SCID that used MLV 25 tions include some protection in ADA SCID due to the inherent vectors targeting either peripheral blood T cells or BM HSCs. However, integrants in transduced T cells were deplete cells. Transduced HSCs SCID-X1 patients with a putatively safer SIN -RV vector (lacking did not show the bias toward these lymphoid-related sites. These LTR enhancers) carrying the IL2R cDNA under control of the EFS investigators had previously shown that subjects who received promoter (www. Common clinical protocols *Republished in 2012 on the 40th anniversary of the original report. As with the earlier trials, 478 American Society of Hematology the target cell is BM CD34 cells and no conditioning is being viral vector) that introduces the desired mutation correction. The trials are being done under separate regulatory oversight may use the donor sequence as a template to bridge the gap at the (France, United Kingdom, United States), but the data combined for double-stranded break, copying in corrective sequence present in analyses. Initial reports have described the results with 9 treated the donor. A succession of engineered endonucleases have been subjects. No clonal expansions or clinical minimal direct comparative data to define which is the most active leukoproliferative events have occurred to date.

order voveran 50mg free shipping

In the clinical trials so far 50mg voveran fast delivery, 500 patients have successfully used these extended half-life products regularly for 1 year to prevent spontaneous bleeding buy cheap voveran 50 mg line, to treat successfully any bleeding episodes cheap voveran 50 mg free shipping, and to provide effective coagulation for major surgery discount 50mg voveran amex. Essentially all infusions were well tolerated and effective voveran 50 mg without prescription. These promising new therapies should allow patients to use fewer infusions to maintain appropriate clotting factor activity levels in all clinical settings. The term usually refers to either promising success in gene therapy for hemophilia B, a cure for hemophilia A, factor VIII (FVIII), or hemophilia B, FIX deficiency. Therefore, improved factor The incidence of hemophilia A is the same in all geographic regions, 1 preparations are needed. When severe, defined as clotting activity 1%, patients are at risk Various methods are in development to improve the treatment of for spontaneous, life threatening bleeding episodes. The different approaches, including the use of moderate hemophilia, between 1% and 5% clotting activity, or with bioengineered coagulation factors, can be summarized in 4 groups, mild hemophilia will usually suffer abnormal bleeding only after efforts to extend the half-life (t1/2) of FVIII, FIX, or FVIIa and other minor trauma or surgery. Each group will be When untreated, patients with severe hemophilia have a short life discussed separately. As the first extended t1/2 factor product expectancy of 20 years but, over the past several decades, the 2,3 approved for clinical use, eftrenonacog alfa (FIXFc) will be clinical management for hemophilia has improved dramatically. As few as only 1 or 2 States for clinical use in children and adults with hemophilia B. The bleeding episodes in a single joint can initiate the process of protein is composed of a single molecule of recombinant FIX inflammation, leading to synovitis and chronic joint damage or covalently fused to the dimeric Fc (fragment crystallizable) domain hemophilic arthropathy. Shown are expected FIX activity after doses (50 IU/kg body weight) of rFIXFc or rFIX administered intravenously at time 0 hours and followed for the specified intervals. The immediate postdose recovery giving a FIX activity level of 50%is as expected for both the short-acting rFIX and the extended t1/2 rFIXFc. The red line indicates the hours when the FIX activity level is 2% in this individual after taking the short-acting rFIX, and thus when he would be at risk of bleeding. Although the lines represent 1 individual’s experience with the 2 different FIX preparations, the vertical lines represent the range of FIX activity levels for most persons with hemophilia. The IgG constant region (Fc) has been back to the surface and released at neutral pH, thereby escaping molecularly engineered to create fusion proteins that prolong the degradation by the lysosome. Although Fc fusions are typically circulating t1/2 of Fc fusion–based drugs used clinically (eg, expressed as homodimers formed through a disulfide bond, this etanercept, romiplostim) and others in development. FIX, FVIIa, or B-domain-deleted FVIII, with secretion as the dimeric Fc molecule with one molecule of clotting protein, was With Fc fusion proteins, the neonatal Fc receptor interacting with effective and demonstrated increases in plasma t. New factor products for hemophilia Factor Modification Clinical benefit/status* FIX rFIX-Fc Fusion to FcIG Approved US and Canada; 3–5 fold increase t1/2 rFIX-FP Fusion to albumin 3–5 fold increase t1/2; phase 3 completed N9-GP 40 kDa PEG on activation peptide Phase 3 completed FVIII rFVIII-Fc Fusion to FcIgG Approved US; 1. Cell lines are grown in serum-free suspension medium in the (www. Purification of rFIXFc monomer is by pants were representative of the general adult population with column chromatography with the use of a protein A capture step and severe hemophilia B (endogenous FIX level of 2 IU/dL or 2% 2 anion exchange steps, Fractogel DEAE and Q Sepharose. The last of normal levels) and were 12 years of age or older. Reflecting ion exchange step involves pseudoaffinity elution19 from a Q different clinical regimens, the study included 4 treatment groups. Sepharose resin with low ionic strength CaCl2 to obtain rFIXFc with Group 1 received weekly dose-adjusted prophylaxis (50 IU of highest specific activity. Group 2 received interval-adjusted Eftrenonacog alfa (FIXFc) demonstrated safety and prolonged prophylaxis (100 IU/kg every 10 days to start) with the interval efficacy in bleeding models compared with rFIX in mice, rats, adjusted as needed as for group 1. Group 3 received treatment as hemophilic dogs, and cynomolgus monkeys. Group 4 received treatment as needed for surgical proce- HEK293H cells. In a subgroup of Group 1 participants, comparative sequen- lation of Asp 64 than did rFIX or pdFIX. Peters et al19 showed that tial pharmacokinetic assessments of rFIX (BeneFIX; Pfizer) and rFIXFc has a 3- to 4-fold longer terminal t1/2 in mice expressing rFIXFc were performed after infusion of a dose of 50 IU/kg and human neonatal Fc receptor (FcRn) and beta 2 microglobulin ( 2m) repeated at week 26. The primary efficacy end point was the compared with rFIX, whereas both proteins have similar short annualized bleeding rate and safety end points included the develop- terminal half-lives in mice lacking FcRn (FcRn/ 2m KO).

9 of 10 - Review by D. Sanford
Votes: 126 votes
Total customer reviews: 126



Get Involved

> Newsletters
About Us
> Contact Information
> Mission and vision
> Who support us
> In the press
> CoopXixuaú
Where we are
> Education
> Healthcare
> Conservation
> Scientific Research
> Transport
> Solar energy and Internet
> Getting Reddy Project
> Trip to the Amazon - Special
> Trip to the Amazon - Information
> Trip to the Amazon - Booking
Media centre
> Images
> Videos
> Sounds